Analysts' ratings for Centene CNC over the last quarter vary from bullish to bearish, as provided by 8 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated Centene and provided 12-month price targets. The average target is $83.0, accompanied by a high estimate of $90.00 and a low estimate of $74.00. Observing a 6.41% increase, the current average has risen from the previous average price target of $78.00.
Investigating Analyst Ratings: An Elaborate Study
An in-depth analysis of recent analyst actions unveils how financial experts perceive Centene. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Stephen Baxter | Wells Fargo | Raises | Overweight | $90.00 | $82.00 |
| Ryan MacDonald | Truist Securities | Raises | Buy | $86.00 | $83.00 |
| Kevin Caliendo | UBS | Raises | Neutral | $79.00 | $72.00 |
| Sarah James | Cantor Fitzgerald | Raises | Overweight | $90.00 | $82.00 |
| Stephen Baxter | Wells Fargo | Raises | Equal-Weight | $82.00 | $74.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $82.00 | - |
| Stephen Baxter | Wells Fargo | Raises | Equal-Weight | $74.00 | $71.00 |
| David Windley | Jefferies | Lowers | Buy | $81.00 | $82.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Centene. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Centene compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Centene's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Centene's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Centene analyst ratings.
Discovering Centene: A Closer Look
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 24 million medical members as of June 2023, mostly in Medicaid (67% of membership), the individual exchanges (14%), and Medicare Advantage (6%) plans. The company also serves traditional Medicare users with its Medicare Part D pharmaceutical program.
Centene's Economic Impact: An Analysis
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Centene displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 6.07%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Centene's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 1.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Centene's ROE stands out, surpassing industry averages. With an impressive ROE of 1.84%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Centene's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.56% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Centene's debt-to-equity ratio surpasses industry norms, standing at 0.76. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst Ratings: What Are They?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
